COVID-19Updates See latest Press Relases Celularity Inc. to Host Investor and Analyst Research & Development Day 22 Apr 2024 7 Minutes 0 729 ... Celularity Abstract “Emerging Technologies for the Management and Protection of Tendon Injuries: Decellularized Placental Biomaterials” Accepted at ORS Tendon Conference 2024 18 Apr 2024 9 Minutes 0 724 ... Celularity Announces Net Sales Trending Ahead of Expectations for First Quarter 2024; Implements Planned 2024 SG&A Reductions and Manufacturing Ramp for Advanced Biomaterial Products 15 Apr 2024 10 Minutes 0 730 ... Celularity to Present Data Showing Senescent Cell Elimination by Off-the-Shelf Natural Killer Cells Derived from Human Placental Cells 8 Apr 2024 8 Minutes 0 725 ... Celularity Receives Healthcare Common Procedure Coding System (HCPCS) Q Code Approval from the U.S. Centers for Medicare & Medicaid Services for Biovance® 3L 26 Mar 2024 8 Minutes 0 731 ... Load more
Celularity Inc. to Host Investor and Analyst Research & Development Day 22 Apr 2024 7 Minutes 0 729 ...
Celularity Abstract “Emerging Technologies for the Management and Protection of Tendon Injuries: Decellularized Placental Biomaterials” Accepted at ORS Tendon Conference 2024 18 Apr 2024 9 Minutes 0 724 ...
Celularity Announces Net Sales Trending Ahead of Expectations for First Quarter 2024; Implements Planned 2024 SG&A Reductions and Manufacturing Ramp for Advanced Biomaterial Products 15 Apr 2024 10 Minutes 0 730 ...
Celularity to Present Data Showing Senescent Cell Elimination by Off-the-Shelf Natural Killer Cells Derived from Human Placental Cells 8 Apr 2024 8 Minutes 0 725 ...
Celularity Receives Healthcare Common Procedure Coding System (HCPCS) Q Code Approval from the U.S. Centers for Medicare & Medicaid Services for Biovance® 3L 26 Mar 2024 8 Minutes 0 731 ...